Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Veenat 100
Veenat 100 contains Imatinib, a powerful tyrosine kinase inhibitor designed to treat specific cancers by targeting and inhibiting the activity of certain proteins involved in cancer cell proliferation. It is widely recognized for its effectiveness in managing chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs).
Uses of Veenat 100
Chronic Myeloid Leukemia (CML): Effective in the treatment of CML, particularly in patients with Philadelphia chromosome-positive (Ph+) CML in chronic phase, accelerated phase, or blast crisis.
Gastrointestinal Stromal Tumors (GISTs): Used for the treatment of GISTs that are unresectable or metastatic and express the CD117 protein.
Acute Lymphoblastic Leukemia (ALL): Can be used in the treatment of ALL with specific genetic mutations.
Other Malignancies: May be used for other cancers with specific genetic targets.
Benefits of Veenat 100
Targeted Therapy: Specifically targets and inhibits the BCR-ABL tyrosine kinase enzyme and other related pathways, leading to reduced cancer cell proliferation.
Effective in CML and GISTs: Proven efficacy in treating chronic myeloid leukemia and gastrointestinal stromal tumors, offering significant improvements in survival and quality of life.
Convenient Oral Administration: Available in capsule form, facilitating ease of use and adherence to treatment regimens.
Reduces Tumor Burden: Helps in shrinking tumors and managing cancer progression effectively.
Mechanism of Action of Veenat 100
Inhibition of Tyrosine Kinases: Imatinib, the active ingredient, inhibits the activity of tyrosine kinases such as BCR-ABL, which are involved in cancer cell proliferation.
Interruption of Signal Transduction: By blocking these enzymes, Veenat 100 disrupts the signaling pathways that drive cancer cell growth and division.
Selective Targeting: Specifically targets cancer cells with the BCR-ABL fusion protein, minimizing impact on normal cells and reducing side effects.